Rekrutierung von Patienten – schnell, fair, qualitätvoll
emovis ist nicht nur bekannt für seine hohen Rekrutierungszahlen. Sondern vor allem auch für die Einhaltung bzw. das Übertreffen von prognostizierten Rekrutierungsraten an Studienteilnehmern. Der Grund: zum einen zeigt emovis viel Erfahrung und Innovationsbereitschaft in der Rekrutierung von Patienten, zum andern hat die emovis-Geschäftsführung schlicht die Gewohnheit, Rekrutierungszahlen konservativ zu schätzen. Für emovis ein Gebot der Fairness. Nicht wenige Auftraggeber waren bis dato schon verblüfft – und erfreut.
Suche nach vergangenen Studien und Rekrutierungszahlen
| Start | Indikation | Sponsor | Zeitraum | Rekrutiert | Studiennummer |
|---|---|---|---|---|---|
| 2017 | Schlafstörung | Eisai Inc. | 10 Monate | 93 | EudraCT-2015-004347-39 |
| 2017 | Reizdarmsyndrom | Dr. Willmar Schwabe | 9 Monate | 23 | EudraCT-2014-004702-14 |
| 2017 | Depression | Janssen-Cilag | 11 Monate | 12 | EudraCT-2016-001929-14 |
| 2017 | Astellas | 1 Monat | 22 | EudraCT-2014-004996-22 | |
| 2017 | Prädiabetes | Glycemicon | 13 Monate | 60 | |
| 2017 | Impfung | Pfizer Pharma | 16 Monate | 26 | EudraCT-2016-003866-14 |
| 2016 | Harnwegsinfektion | Repha | 20 Monate | 22 | EudraCT-2013-004653-25 |
| 2017 | Allergrische Rhinitis | ALK-Abelló | 1 Monat | 8 | EudraCT-2017-000971-97 |
| 2017 | COPD | Astra Zeneca, Pearl | 1 Monat | 18 | EudraCT-2016-000154-34 |
| 2017 | COPD | Verona Pharma | 3 Monate | 16 | EudraCT-2016-005205-40 |
| 2017 | Akute Infektionen | Medicago | 2 Monate | 92 | |
| 2018 | Demenz vom Alzheimer-Typ | Eisai Inc. | 9 Monate | 13 | EudraCT-2016-003928-23 |
| 2018 | Schlafstörung | Idorsia | 12 Monate | 239 | EudraCT-2017-004642-20 |
| 2018 | Akute Infektionen | Medicago | 2 Wochen | 52 | EudraCT-2018-001894-26 |
| 2018 | Arthrose | Regeneron | 2 Wochen | 23 | EudraCT-2017-001702-15 |
| 2018 | Nagelpilz | Moberg Pharma | 5 Monate | 127 | EudraCT-2016-001204-39 |
| 2018 | Schlafstörung | Janssen-Cilag | 4 Monate | 32 | EudraCT-2017-000980-33 |
| 2018 | Prämenstruelles Syndrom | Asarina | 6 Monate | 20 | EudraCT-2017-000822-37 |
| 2018 | Uterusmyom | Bayer AG | 8 Monate | 8 | EudraCT-2016-002855-48 |
| 2016 | Nagelpilz | Almirall | 4 Monate | 59 | EudraCT-2015-000561-31 |
| 2015 | Arthrose | Regeneron | 6 Monate | 48 | |
| 2015 | COPD | Novartis | 4 Monate | 15 | EudraCT-2013-003127-11 |
| 2014 | Diabetes mellitus | Hanmi | 5 Monate | 1 | EudraCT-2013-004250-13 |
| 2013 | Depression | Allergan | 12 Monate | 25 | EudraCT- 2012-001950-25 |
| 2012 | COPD | Allergan, Almirall, Astra Zeneca | 6 Monate | 27 | EudraCT-2011-001524-38 |
| 2011 | COPD | Glaxo Smith Kline Research & Development Ltd. | 6 Monate | 20 | EudraCT-2010-021802-39 |
| 2008 | Angsterkrankung (GAD) | H. Lundbeck | 3 Monate | 10 | EudraCT-2008-001766-90 |
| 2008 | Depression | Takeda | 8 Monate | 28 | EudraCT-2008-001580-11 |
| 2008 | Diabetes mellitus | Lilly Deutschland | 4 monate | 4 | EudraCT -2008-004207-63 |
| 2018 | Migräne | Merck Sharp & Dohme Corp. | 2 Monate | 55 | |
| 2006 | Metrorrhagie | Bayer AG | 6 Monate | 11 | EudraCT- 2005-004340-32 |
| 2006 | Morbus Parkinson | Axxonis | 2 Monate | 1 | EudraCT-2006-003732-30 |
| 2006 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim | 3 Monate | 21 | EudraCT-2005-006128-13 |
| 2003 | Diabetes mellitus | Glaxo Smith Kline Research & Development Ltd. | 8 Monate | 5 | |
| 2009 | Demenz vom Alzheimer-Typ | H. Lundbeck | 9 Monate | 4 | |
| 2017 | Psoriasis | Novartis | 4 Monate | 4 | EudraCT-2015-005170-38 |
| 2017 | Fettstoffwechselstörung | Esperion Therapeutics | 9 Monate | 4 | |
| 2012 | Demenz vom Alzheimer-Typ | Avraham Pharmaceuticals Ltd. | 17 Monate | 32 | EudraCT-2010-021926-37 |
| 2015 | Depression | Alkermes | 5 Monate | 14 | EudraCT-2014-000380-41 |
| 2017 | Migräne | CoLucid Pharmaceuticals | 4 Monate | 17 | EudraCT-2015-005689-40 |
| 2017 | Depression | Shire Pharmaceuticals Group Plc | 3 Monate | 12 | EudraCT-2016-001929-14 |
| 2018 | Schlafstörung | Idorsia | 1 Monat | 1 | EudraCT-2017-004644-38 |
| 2018 | Depression | Janssen-Cilag | 3 Monate | 32 | EudraCT-2017-000980-33 |
| 2019 | Depression | Janssen-Cilag | 3 Monate | 14 | EudraCT-2019-000695-41 |
| 2019 | Reizdarmsyndrom | Cosmo Pharmaceuticals | 4 Monate | 62 | EudraCT-2016-004977-42 |
| 2019 | Herzinfarkt | Novartis | 4 Monate | 35 | EudraCT-2018-003786-34 |
| 2019 | Prämenstruelles Syndrom | Asarina | 6 Monate | 91 | EudraCT-2017-000822-37 |
| 2019 | Diabetes mellitus | Novo Nordisk | 4 Monate | 14 | EudraCT-2017-003219-20 |
| 2019 | Statin Intoleranz | Esperion Therapeutics | 4 Months | 3 | EudraCT2016-003485-11 |
| 2019 | Übergewicht | Novo Nordisk | 3 Monate | 23 | Eudra CT-2017-003380-35 |
| 2019 | Schlafstörung | Idorsia | 4 Monate | 7 | EudraCT-2017-004644-38 |
| 2019 | Akute Infektionen | Sanofi-Pasteur | 1 Monat | 99 | EudraCT-2019-000655-14 |
| 2019 | Alopecia Areata | Pfizer Pharma | 3 Monate | 7 | EudraCT-2018-001714-14 |
| 2019 | Atopic Dermatitis | Pfizer Pharma | 3 Monate | 8 | EudraCT-2018-003050-24 |
| 2019 | Hyperhidrosis, Hyperhidrosis | Wolff | 3 Monate | 27 | EudraCT-2017-004534-29 |
| 2019 | Herpes Genitalis | Heidelberg ImmunoTherapeutics | 8 Monate | 56 | EudraCT-2019-000880-26 |
| 2019 | Psoriasis | Pfizer Pharma | 8 Monate | 5 | EudraCT-2018-003051-38 |
| 2019 | Reizdarmsyndrom | Repha | 7 Monate | 4 | EudraCT-2019-000245-12 |
| 2019 | Reizdarmsyndrom | SymbioPharm | 7 Monate | 6 | EudraCT-2018-004626-28 |
| 2019 | Depression | Allergan | 7 Monate | 4 | EudraCT-2018-002782-19 |
| 2020 | Impfung | Vakzine Projekt Management | 2 Monate | 156 | EudraCT-2019-002706-46 |
| 2000 | Depression | Boehringer Ingelheim | 12 Monate | 60 | |
| 2000 | Angsterkrankung (Phobie) | Solvay | 3 Monate | 23 | |
| 2001 | Angsterkrankung (Panik) | Pfizer Pharma | 3 Monate | 4 | |
| 2001 | Angsterkrankung (Panik) | Wyeth | 12 Monate | 49 | |
| 2001 | Depression | Servier Forschung und Pharma-Entwicklung | 3 Monate | 9 | |
| 2002 | Angsterkrankung (Phobie) | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 25 | |
| 2002 | Angsterkrankung (GAD) | Orion Pharma | 5 Monate | 35 | |
| 2002 | Depression | Dr. Willmar Schwabe | 10 Monate | 13 | |
| 2002 | Schizophrenie | Janssen-Cilag | 6 Monate | 7 | |
| 2002 | RLS (Syndrom der unruhigen Beine) | Glaxo Smith Kline Research & Development Ltd. | 2 Wochen | 9 | |
| 2002 | RLS (Syndrom der unruhigen Beine) | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 16 | |
| 2002 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim | 3 Monate | 35 | |
| 2002 | Migräne | Glaxo Smith Kline Research & Development Ltd. | 4 Monate | 55 | |
| 2002 | Migräne | Bayer AG | 3 Monate | 10 | |
| 2002 | Depression | Servier Forschung und Pharma-Entwicklung | 3 Monate | 22 | |
| 2003 | Abhängigkeit (Nikotin) | Glaxo Smith Kline Research & Development Ltd. | 4 Tage | 101 | |
| 2003 | Demenz vom Alzheimer-Typ | Janssen-Cilag | 4 Monate | 5 | |
| 2003 | Depression | Servier Forschung und Pharma-Entwicklung | 2 Monate | 24 | |
| 2003 | RLS (Syndrom der unruhigen Beine) | UCB S.A. | 6 Wochen | 32 | |
| 2003 | Depression | H. Lundbeck | 7 Monate | 21 | |
| 2003 | Demenz vom Alzheimer-Typ | Sanofi-Synthelabo | 15 Monate | 15 | |
| 2003 | Depression | Dr. Willmar Schwabe | 14 Monate | 58 | |
| 2004 | RLS (Syndrom der unruhigen Beine) | Imerem | 6 Monate | 20 | EudraCT-2005-000428-18 |
| 2004 | Polyneuropathie, diabetisch | INC Research | 4 Monate | 19 | |
| 2004 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim | 3 Monate | 49 | |
| 2004 | Depression | Lilly Deutschland | 3 Monate | 50 | |
| 2004 | Demenz vom Alzheimer-Typ | Glaxo Smith Kline Research & Development Ltd. | 8 Monate | 2 | EudraCT-2004-000985-12 |
| 2004 | Depression | Imerem, Schwarz Pharma AG | 6 Monate | 5 | |
| 2004 | Depression | Wyeth | 3 Monate | 27 | EudraCT-2004-000562-13 |
| 2004 | Depression | Glaxo Smith Kline Research & Development Ltd. | 8 Monate | 31 | |
| 2004 | Reizdarmsyndrom | Glaxo Smith Kline Research & Development Ltd. | 5 Monate | 49 | EudraCT-2004-000848-24 |
| 2004 | Angsterkrankung (Phobie) | Glaxo Smith Kline Research & Development Ltd. | 5 Monate | 35 | EudraCT-2004-000848-24 |
| 2004 | Angsterkrankung (GAD) | Lilly Deutschland | 10 Monate | 14 | |
| 2005 | Depression | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 1 | EudraCT-2004-003803-19 |
| 2005 | Reizdarmsyndrom | Yamanouchi Pharma | 2 Monate | 12 | EudraCT-2004-003880-61 |
| 2005 | Angsterkrankung (GAD) | Lilly Deutschland | 8 Monate | 17 | EudraCT-2004-002626-22 |
| 2005 | Depression | Boehringer Ingelheim | 7 Monate | 9 | |
| 2005 | Prämenstruelles Syndrom | Wyeth | 8 Monate | 3 | EudraCT-2004-005173-27 |
| 2005 | Bronchitis | Bionorica | 2 Wochen | 3 | EudraCT-2005-003249-15 |
| 2005 | Angsterkrankung (Panik) | Elbion | 1 Monat | 12 | EudraCT-2005-005708-17 |
| 2006 | RLS (Syndrom der unruhigen Beine) | Imerem | 2 Monate | 12 | |
| 2006 | Depression | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 21 | EudraCT-2006-001877-13 |
| 2006 | Depression | Servier Forschung und Pharma-Entwicklung | 3 Monate | 46 | EudraCT-2004-004009-10 |
| 2006 | Depression | Sanofi-Aventis | 4 Monate | 42 | EudraCT - 2004-002327-41 |
| 2006 | RLS (Syndrom der unruhigen Beine) | Imerem, Schwarz Pharma AG | 2 Monate | 11 | EudraCT-2004-001589-42 |
| 2006 | Schlafstörung | Sanofi-Aventis | 18 Monate | 31 | EudraCT- 2005-003082-16 |
| 2006 | RLS (Syndrom der unruhigen Beine) | Axxonis | 10 Monate | 26 | EudraCT-2004-001589-42 |
| 2006 | Angsterkrankung (GAD) | Astra Zeneca | 9 Monate | 7 | EudraCT- 2005-005055-18 |
| 2006 | Depression | Astra Zeneca | 4 Monate | 13 | EudraCT- 2005-003745-14 |
| 2006 | Reizdarmsyndrom | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 28 | |
| 2006 | RLS (Syndrom der unruhigen Beine) | Glaxo Smith Kline Research & Development Ltd. | 4 Monate | 3 | |
| 2006 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim | 7 Monate | 21 | EudraCT-2005-005225-54 |
| 2006 | Hypertonie | Astra Zeneca | 6 Monate | 50 | EudraCT -2005-005718-19 |
| 2006 | Angsterkrankung (Phobie) | Glaxo Smith Kline Research & Development Ltd. | 5 Monate | 16 | EudraCT- 2006-003597-10 |
| 2007 | Depression | Pierre Fabre | 5 Monate | 11 | EudraCT-2006-002404-34 |
| 2007 | Angsterkrankung (GAD) | Sanofi-Aventis | 6 Monate | 16 | EudraCT 2006-002253-71 |
| 2007 | Migräne | Merck Sharp & Dohme Corp. | 5 Monate | 35 | EudraCT-2006-006187-35 |
| 2007 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim | 4 Monate | 34 | EudraCT-2006-006431-42 |
| 2007 | Hypertonie | DaiichiSankyo Deutschland | 19 Monate | 19 | EudraCT-2008-008260-28 |
| 2007 | Neuralgie (Zoster) | Grünenthal | 4 Monate | 8 | |
| 2007 | Polyneuropathie, diabetisch | Grünenthal | 4 Monate | 8 | EudraCT-2006-003132-29 |
| 2007 | Morbus Parkinson | Imerem | 3 Monate | 1 | |
| 2007 | Polyneuropathie, diabetisch | Swedish Orphan | 2 Monate | 1 | EudraCT- 2006-004007-19 |
| 2007 | Schlafstörung | Sanofi-Aventis | 12 Monate | 14 | EudraCT-2006-006677-25 |
| 2007 | Depression | Servier Forschung und Pharma-Entwicklung | 10 Monate | 16 | EudraCT-2006-004716-48 |
| 2007 | Depression | Sanofi-Aventis | 10 Monate | 36 | EudraCT-2004-002328-16 |
| 2007 | Depression | Glaxo Smith Kline Research & Development Ltd. | 10 Monate | 36 | EudraCT-2005-003400-11 |
| 2007 | Sexuelle Disfunktionen | Boehringer Ingelheim | 11 Monate | 60 | EudraCT-2007-000032-68 |
| 2008 | Hypertonie | Takeda | 2 Monate | 10 | EudraCT-2007-002583-10 |
| 2008 | Fettstoffwechselstörung | Merck Sharp & Dohme Corp. | 2 Monate | 33 | EudraCT 2011-001007-12 |
| 2008 | Sexuelle Disfunktionen | Bayer AG | 4 Monate | 13 | Eudract-2006-004397-27 |
| 2008 | Depression | H. Lundbeck | 6 Monate | 30 | EudraCT-2008-001580-11 |
| 2008 | Diabetes mellitus | Merck Sharp & Dohme Corp. | 1 Monat | 4 | EudraCT-2007-000145-35 |
| 2008 | Depression | Sanofi-Aventis | 6 Monate | 29 | EudraCT-2004-002328-16 |
| 2008 | Schmerzbehandlung | Lilly Deutschland | 6 Monate | 12 | EudraCT-2006-003484-31 |
| 2008 | Migräne | Merck Sharp & Dohme Corp. | 3 Monate | 55 | EudraCT-2006-004257-14 |
| 2008 | Überaktive Blase (OAB) | Pfizer Pharma | 4 Monate | 18 | EudraCT-2004-000476-13 |
| 2008 | Reizdarmsyndrom | Menarini | 3 Monate | 24 | EudraCT-2008-000214-71 |
| 2008 | Impfung | Glaxo Smith Kline Research & Development Ltd. | 1 Monat | 44 | |
| 2008 | Demenz vom Alzheimer-Typ | IFE Europe | 1 Monat | 3 | EudraCT-2008-002758-39 |
| 2008 | Angsterkrankung (GAD) | Takeda | 2 Monate | 7 | EudraCT-2008-001766-90 |
| 2008 | Hypertonie | Novartis | 4 Monate | 17 | EudraCT- 2006-006068-44 |
| 2008 | Impfung | Merck Sharp & Dohme Corp. | 8 Monate | 844 | EudraCT-2007-004020-20 |
| 2009 | Diabetes mellitus | Lilly Deutschland | 2 Monate | 4 | EudraCT-2009-009889-13 |
| 2009 | Schlafstörung | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 29 | EudraCT-2008-006345-72 |
| 2009 | Depression | Takeda | 1 Monat | 49 | EudraCT-2008-001581-91 |
| 2009 | Abhängigkeit (Alkohol) | Pierrell Research | 15 Monate | 28 | EudraCT-2007-002315-92 |
| 2009 | Arthrose | Lilly Deutschland | 4 Monate | 12 | EudraCT-2009-010008-27 |
| 2009 | Diabetes mellitus | Boehringer Ingelheim | 8 Monate | 2 | EudraCT-2008-008296-33 |
| 2009 | RLS (Syndrom der unruhigen Beine) | Pfizer Pharma | 6 Monate | 16 | EudraCT-2008-005889-32 |
| 2009 | Diabetes mellitus | Novartis | 7 Monate | 6 | EudraCT-2008-002758-39 |
| 2009 | Demenz vom Alzheimer-Typ | Servier Forschung und Pharma-Entwicklung | 7 Monate | 7 | |
| 2009 | Depression | H. Lundbeck | 2 Monate | 6 | EudraCT-2007-001871-13 |
| 2009 | Demenz vom Alzheimer-Typ | H. Lundbeck | 7 Monate | 10 | |
| 2009 | Verhütung | Bayer AG | 8 Monate | 148 | EudraCT-2009-009177-10 |
| 2009 | Abhängigkeit (Alkohol) | H. Lundbeck | 10 Monate | 121 | EudraCT-2007-002315-92 |
| 2010 | Depression | Glaxo Smith Kline Research & Development Ltd. | 4 Monate | 22 | EudraCT- 2009-010339-42 |
| 2010 | Demenz vom Alzheimer-Typ | Lilly Deutschland | 9 Monate | 4 | EudraCT-2008-002758-39 |
| 2010 | Depression | Sanofi-Aventis | 7 Monate | 33 | EudraCT-2009-010339-42 |
| 2010 | Demenz vom Alzheimer-Typ | JSW Lifescience | 6 Monate | 4 | |
| 2010 | Obstipation | Shire Pharmaceuticals Group Plc | 32 Monate | 16 | EudraCT-2009-015719-42 |
| 2010 | Migräne | Symbicort, Merck Sharp & Dohme Corp. | 1 Monat | 27 | EudraCT-2010-019288-13 |
| 2010 | Depression | Analyze & Realize, Leiber | 5 Monate | 95 | |
| 2010 | Impfung | Sanofi-Pasteur | 2 Monate | 108 | EudraCT-2010-021068-13 |
| 2010 | Impfung | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 40 | |
| 2010 | Prophylaxe (Erkältung) | Analyze & Realize, Leiber | 1 Monat | 60 | |
| 2011 | Diabetes mellitus | Boehringer Ingelheim | 15 Monate | 18 | EudraCT-2010-021375-92 |
| 2011 | Psychiatrische Diagnosen, sonstige | Dr. Willmar Schwabe | 4 Monate | 50 | EudraCT- 2010-022114-12 |
| 2011 | Depression | Astra Zeneca | 5 Monate | 18 | EudraCT-2010-019925-33 |
| 2011 | ADHS | Novartis | 4 Monate | 70 | EudraCT-2011-004668-31 |
| 2011 | Hypertonie | Servier Forschung und Pharma-Entwicklung | 6 Monate | 25 | EudraCT- 2010-020945-28 |
| 2011 | COPD | Glaxo Smith Kline Research & Development Ltd. | 9 Monate | 21 | EudraCT-2010-021802-39 |
| 2011 | Depression | Takeda | 5 Monate | 46 | EudraCT- 2011-005298-22 |
| 2011 | Diabetes mellitus | MetaCure Germany | 10 Monate | 3 | EudraCT- 2010-020945-28 |
| 2011 | Psychiatrische Diagnosen, sonstige | Weleda AG | 9 Monate | 201 | EudraCT- 2010-024189-23 |
| 2011 | Venöse Insuffizienz | OM Pharma (Vifor Pharma) | 4 Monate | 9 | EudraCT-2009-013391-44 |
| 2011 | RLS (Syndrom der unruhigen Beine) | UCB S.A. | 4 Monate | 47 | EudraCT- 2011-000053-23 |
| 2011 | Demenz vom Alzheimer-Typ | Genetech | 4 Monate | 6 | EudraCT-2010-021926-37 |
| 2011 | ADHS | Shire Pharmaceuticals Group Plc | 7 Monate | 10 | EudraCT-2010-018579-12 |
| 2011 | Demenz vom Alzheimer-Typ | Avraham Pharmaceuticals Ltd. | 17 Monate | 32 | EudraCT-2010-021926-37 |
| 2012 | Reizdarmsyndrom | Laves Arzneimittel | 2 Jahre | 65 | |
| 2012 | COPD | Almirall | 5 Monate | 27 | EudraCT-2011-001524-38 |
| 2012 | Abhängigkeit (Nikotin) | Pfizer Pharma | 2 Jahre | 371 | EudraCT- 2010-022914-15 |
| 2012 | Depression | Shire Pharmaceuticals Group Plc | 12 Monate | 44 | EudraCT-2011-003018-17 |
| 2012 | Depression | Merck Sharp & Dohme Corp. | 10 Monate | 5 | EudraCT-2011-005200-15 |
| 2012 | Depression | H. Lundbeck | 8 Monate | 19 | EudraCT-2012-001380-76 |
| 2013 | Essstörung (Binge Disorder) | Shire Pharmaceuticals Group Plc | 2 Monate | 2 | Eudra CT-2012-003310-14 |
| 2013 | COPD | Glaxo Smith Kline Research & Development Ltd. | 1 Woche | 2 | EudraCT-2011-001644-29 |
| 2013 | Obstipation | Ferring Pharmaceuticals | 6 Monate | 24 | EudraCT-2012-005588-28 |
| 2013 | Impfung | Glaxo Smith Kline Research & Development Ltd. | 1 Monat | 16 | EudraCT-2015-000965-30 |
| 2013 | COPD | Almirall, Astra Zeneca | 3 Monate | 20 | EudraCT-2013-000116-14 |
| 2014 | Reizdarmsyndrom | Menarini | 6 Monate | 15 | EudraCT-2013-000894-56 |
| 2014 | Essstörung (Binge Disorder) | Shire Pharmaceuticals Group Plc | 1 Monat | 1 | EudraCT-2012-004457-88 |
| 2014 | Impfung | Sanofi-Pasteur | 11 Monate | 6 | EudraCT-2013-000775-32 |
| 2014 | COPD | Novartis | 2 Monate | 21 | EudraCT-2013-001477-25 |
| 2014 | COPD | Glaxo Smith Kline Research & Development Ltd. | 6 Wochen | 12 | EudraCT-2011-005914-12 |
| 2014 | COPD | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 15 | EudraCT-2014-000611-14 |
| 2015 | Depression | Alkermes | 6 Monate | 48 | EudraCT-2014-000379-14 |
| 2015 | COPD | Astra Zeneca | 4 Monate | 11 | EudraCT-2014-004715-37 |
| 2015 | Abhängigkeit (Nikotin) | Philip Morris | 1 Monat | 28 | EudraCT- 2013-002447-29 |
| 2015 | Fibromyalgie | DaiichiSankyo Deutschland | 7 Monate | 28 | EudraCT-2013-005164-26 |
| 2015 | COPD | Pearl | 4 Monate | 29 | EudraCT-2014-004712-10 |
| 2016 | Akute Infektionen | Vertex | 3 Monate | 1 | EudraCT- 2014-004068-39 |
| 2016 | Depression | Janssen-Cilag | 10 Monate | 3 | EudraCT-2014-004587-38 |
| 2016 | Allergie (Gräserpollen) | Allergopharma | 2 Monate | 33 | EudraCT- 2015-002409-13 |
| 2016 | Arthrose | PBB Entrepreneur Ltd. | 4 Monate | 56 | |
| 2016 | Asthma | Astra Zeneca | 1 Monat | 10 | EudraCT- 2004-004042-41 |
| 2016 | Sodbrennen (GERD) | Reckitt Benckiser | 5 Monate | 33 | EudraCT-2014-005261-69 |
| 2016 | Fettstoffwechselstörung | Esperion Therapeutics | 6 Monate | 12 | EudraCT-2016-004115-12 |
| 2015 | Diabetes mellitus | Astra Zeneca | 4 Monate | 9 | EudraCT-2015-002376-24 |
| 2016 | Schmerzbehandlung | Esperion Therapeutics, Boehringer Ingelheim | 5 Monate | 90 | EUdraCT-2015-000404-25 |
| 2016 | Demenz vom Alzheimer-Typ | Reckitt Benckiser, Boehringer Ingelheim | 1 Monat | 1 | EudraCT-2013-005031-24 |
| 2016 | Demenz vom Alzheimer-Typ | Pearl, Boehringer Ingelheim | 6 Monate | 16 | EudraCT-2013-005040-28 |
| 2016 | Verhütung | DaiichiSankyo Deutschland, Estetra SPRL | 5 Monate | 21 | EudraCT-2013-005164-26 |
| 2016 | COPD | Astra Zeneca | 3 Monate | 31 | EudraCT-2015-005444-33 |
| 2016 | Reizdarmsyndrom | SymbioPharm | 5 Monate | 33 | EudraCT- 2011-004593-29 |
| 2016 | Nagelpilz | Polichem | 5 Monate | 60 | EudraCT-2015-000561-31 |
| 2016 | Reizdarmsyndrom | Colibiogen | 4 Monate | 11 | EudraCT-2011-001743-78 |
| 2017 | Demenz vom Alzheimer-Typ | Biogen | 18 Monate | 55 |